The Southern Consortium Node has participated in over 45 research projects in the CTN. See a listing of all of the CTN protocols.
Current/recently completed projects include:
- CTN0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Disorder. This study was conducted at Behavioral Health Services of Pickens County, and the site PI was Susan Sonne, PharmD. This study is complete.
- CTN0089: Integrating Nurse Practitioner Buprenorphine Waiver Training into Graduate Nursing Curriculum. This project was led by Carolyn Bogdon, MSN,FNP-BC, and Karen Hartwell, M.D. This training project is complete.
- CTN0099: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED INNOVATION). MUSC/SCN is actively participating in this study; Lindsay Jennings, M.D., is the site PI. This study is complete.
- CTN0107: Peer Recovery Support: A Bridge to Treatment for Overdose Survivors. The study is being led by the SCN; Kelly Barth, DO is the Lead Investigator, and Erin McClure, Ph.D., is the National Project Director. The recruitment goal was successfully met, and study is now in data analysis.
- CTN0107-A-1:Why Do Patients Decline Buprenorphine from the Emergency Department? This is an add-on study to CTN0107, involving interviews with patients offered buprenorphine in the ED, as well as buprenorphine prescribers in peers working in the ED. Angie Moreland, Ph.D., and Lindsey Jennings, M.D., are co-leading this multi-site project. This study is complete; in data analysis.
- CTN0108: Transcranial Magnetic Stimulation for the Treatment of Cocaine/Methamphetamine Use Disorder. This study is being co-led by the SCN and the Texas Node. This study is complete; in data analysis.
- CTN0109: Randomized, Placebo Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2). Dr. Peter Hendricks at UAB is the site PI for this study; the site is closed.
- CTN0121: Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders (SUD) among Hospitalized Patients. Ellen Eaton, M.D., at UAB is the site. PI for this study; the study is actively enrolling participants.
- CTN0132:Ketamine for Methamphetamine Use Disorder. This study is being conducted at Prisma Health in Greenville, SC. Alain Litwin, M.D., is the site PI. The study is actively enrolling participants.
- CTN0150: Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME) for pregnant and postpartum persons in MOUD. This study is being conducted at the Medical University of South Carolina, and Connie Guille, M.D., is the site PI. This study is complete.
- CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-Site, Double-Blind, Randomized, Placebo-Controlled Trial (TAB). This study is being conducted at Prisma Health in Greenville, SC. Alain Litwin, M.D., is the site PI. Recruitment is expected to start in October 2025.
- CTN-0156: Pilot Development and Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine. This single site study is being conducted at the Medical University of South Carolina, Lindsey Jennings, M.D., is the study PI. Recruitment is expected to start in August 2025.
Associated Studies
- CS#1036: Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder. This trial is a replication study of CTN0068. Dr. Susan Sonne is the site PI, and the study will be conducted at Behavioral Health Services of Pickens County, in Pickens, SC. The study is actively enrolling participants.
